GSK plc Form 6-K Filing Summary

GSK plc announced on July 20, 2026, that the European Medicines Agency (EMA) has accepted a submission to update the label for Bexsero. The proposed update would allow for a single-dose booster of Bexsero for individuals aged 10 years and older who have previously been vaccinated. This booster aims to help reduce the overall burden of Invasive Meningococcal Disease (IMD), particularly in countries with established infant vaccination programs. IMD, caused by Neisseria meningitidis, is a severe illness with a significant fatality rate and potential for long-term health consequences. The submission is supported by Phase 3b study data demonstrating the effectiveness of a single booster dose in individuals aged 10-20 who received the primary vaccination series as infants. Bexsero is currently registered in 61 countries for the prevention of serogroup B invasive meningococcal disease.